24 articles
New research reveals how a key protein causes mesothelial cells to age prematurely, leading to dangerous scarring in dialysis patients.
Widely-used anti-aging drug combination unexpectedly increased kidney injury markers in mice, raising safety concerns for clinical use.
Scientists identify GSDME as a master switch driving abdominal aortic aneurysms through vascular aging, opening new treatment paths.
Dasatinib plus quercetin cleared senescent cells and restored kidney function in diabetic mice, offering hope for human treatment.
Small trial tests whether dasatinib plus quercetin can improve brain blood flow and cognition in at-risk older adults.
Clinical trial tests whether dasatinib plus quercetin can reduce liver scarring in fatty liver disease patients.
Researchers develop BH3 profiling to predict senolytic drug effectiveness, moving beyond one-size-fits-all aging treatments.
Comprehensive review compares natural compounds, synthetic drugs, and exercise for combating age-related bone loss, muscle weakness, and joint degeneration.
Natural compounds like quercetin eliminate harmful senescent cells in the uterus, improving decidualization and reducing migration linked to endometriosis.
Dasatinib and quercetin nanoparticles improve egg quality and fertility in aging mouse ovaries by clearing senescent cells.
Scientists develop mGL392, a precision senolytic that targets aging cells using lipofuscin binding while minimizing systemic toxicity.
New review reveals senolytic therapies can both help and harm cardiovascular health, challenging clinical translation.
